Agios Pharmaceuticals Announces Enrollment Of First Patient In Phase 1 Study Of AG-120 In Advanced Hematologic Malignancies With An IDH1 Mutation
3/19/2014 9:20:15 AM
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the fields of cancer metabolism and inborn errors of metabolism, today announced that the first patient has been dosed in a Phase 1 study of AG-120 in patients with advanced hematologic malignancies with an isocitrate dehydrogenase-1 (IDH1) mutation. AG-120 is an orally available, selective, potent inhibitor of the mutated IDH1 protein, making it the first targeted therapeutic candidate to treat patients with cancers that harbor the IDH1 mutation.
Help employers find you! Check out all the jobs and post your resume.
comments powered by